Adenocarcinoma of the Pancreas Treated With Panitumumab and Gemcitabine Regimen to Investigate Overall Survival as Primary Endpoint

Stopped APPRISE closure prompted by SWOG S0205 not meeting primary endpoint-improving OS. APPRISE enrollment closure due to similar design;no unexpected safety data

Conditions

• Cancer of Pancreas
• Cancer of the Pancreas
• Pancreas Cancer
• Pancreatic Cancer

Interventions

• DRUG: Gemcitabine
• DRUG: panitumumab

Sponsor

Amgen